ArticleClinical and experimental hepatology2026
Hepatitis E virus infection in a single center in Japan.
Article in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Hepatitis E virus (HEV) is an emerging cause of acute hepatitis in developed countries. Older adults may be prone to symptomatic disease due to age-related vulnerability or underlying conditions. Limited data exist regarding risk factors, clinical outcomes, and liver fibrosis markers in elderly populations. Material and methods: We conducted a single-center retrospective review between January 1, 2016, and March 31, 2025. Patients diagnosed with acute HEV infection were included. The FIB-4 index was calculated 3-6 months after clinical recovery and used as a descriptive, exploratory indicator rather than a diagnostic test. Results: Eight patients met the inclusion criteria, with a median age of 68 years (IQR: 63.5-70.5); six (75%) were male. One asymptomatic case was identified through routine blood donor screening. Comorbidities included hypertension ( Conclusions: In this small cohort, most HEV cases occurred in older men. Post-recovery FIB-4 values were numerically higher among symptomatic cases, but this observation is descriptive and hypothesis-generating; the FIB-4 index should not be used during the acute phase. HEV should be considered in older adults presenting with acute liver dysfunction, regardless of dietary or travel history, and fibrosis assessment - when clinically indicated - should rely on comprehensive noninvasive approaches rather than a single score.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.